# OnCo record panitumumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/panitumumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "panitumumab" ;
  schema:name "Panitumumab"@en ;
  schema:description "Panitumumab is a fully human EGFR antibody, the preferred first-line partner for chemotherapy in left-sided, RAS-normal bowel cancer after the PARADIGM trial."@en ;
  schema:url <https://onco.cc/drugs/panitumumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Panitumumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q417775> ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf>, <https://www.nice.org.uk/guidance/ta439>, <https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-EGFR)" ;
  schema:alternateName "Vectibix" ;
  onco:approval "US 2006: EGFR-expressing mCRC after chemotherapy (later RAS wild-type)", "US 2014: First-line RAS wild-type mCRC with FOLFOX", "US 2025: KRAS G12C mCRC with sotorasib", "EU 2007: Metastatic colorectal cancer; RAS wild-type from 2013", "England (NICE) 2017: Previously untreated RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI" ;
  onco:acceleratedApproval "US 2006-09-27: EGFR-expressing metastatic colorectal carcinoma with progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens" ;
  onco:acceleratedApprovalConfirmed "US 2014-05-23: EGFR-expressing metastatic colorectal carcinoma with progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens" ;
  onco:related <https://onco.cc/biomarkers/ras-wild-type/>, <https://onco.cc/biomarkers/kras-g12d/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/paradigm/>, <https://onco.cc/trials/codebreak-300/>, <https://onco.cc/trials/nct06252649/>, <https://onco.cc/trials/nct06820463/>, <https://onco.cc/trials/nct07659795/>, <https://onco.cc/trials/nct07172919/>, <https://onco.cc/trials/prime/>, <https://onco.cc/trials/cairo5/>, <https://onco.cc/trials/foxtrot/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/>, <https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/>, <https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/> .